These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

240 related items for PubMed ID: 1995949

  • 21. Replication of HIV type 1 in rabbit cell lines is not limited by deficiencies in tat, rev, or long terminal repeat function.
    Cho S, Kindt TJ, Zhao TM, Sawasdikosol S, Hague BF.
    AIDS Res Hum Retroviruses; 1995 Dec; 11(12):1487-93. PubMed ID: 8679293
    [Abstract] [Full Text] [Related]

  • 22. Second-site long terminal repeat (LTR) revertants of replication-defective human immunodeficiency virus: effects of revertant TATA box motifs on virus infectivity, LTR-directed expression, in vitro RNA synthesis, and binding of basal transcription factors TFIID and TFIIA.
    Kashanchi F, Shibata R, Ross EK, Brady JN, Martin MA.
    J Virol; 1994 May; 68(5):3298-307. PubMed ID: 8151790
    [Abstract] [Full Text] [Related]

  • 23. Evaluation of relative promoter strengths of the HIV-1-LTR and a chimeric RSV-LTR in T lymphocytic cells and peripheral blood mononuclear cells: promoters for anti-HIV-1 gene therapies.
    Mukhtar M, Duan L, Bagasra O, Pomerantz RJ.
    Gene Ther; 1996 Aug; 3(8):725-30. PubMed ID: 8854098
    [Abstract] [Full Text] [Related]

  • 24. Mutation of the major 5' splice site renders a CMV-driven HIV-1 proviral clone Tat-dependent: connections between transcription and splicing.
    Bohne J, Kräusslich HG.
    FEBS Lett; 2004 Apr 09; 563(1-3):113-8. PubMed ID: 15063733
    [Abstract] [Full Text] [Related]

  • 25. Human immunodeficiency virus Tat transactivation: induction of a tissue-specific enhancer in a nonpermissive cell line.
    Remenick J, Radonovich MF, Brady JN.
    J Virol; 1991 Oct 09; 65(10):5641-6. PubMed ID: 1654461
    [Abstract] [Full Text] [Related]

  • 26. Evidence that a cell cycle regulator, E2F1, down-regulates transcriptional activity of the human immunodeficiency virus type 1 promoter.
    Kundu M, Srinivasan A, Pomerantz RJ, Khalili K.
    J Virol; 1995 Nov 09; 69(11):6940-6. PubMed ID: 7474112
    [Abstract] [Full Text] [Related]

  • 27. A non-proteolytic role for ubiquitin in Tat-mediated transactivation of the HIV-1 promoter.
    Brès V, Kiernan RE, Linares LK, Chable-Bessia C, Plechakova O, Tréand C, Emiliani S, Peloponese JM, Jeang KT, Coux O, Scheffner M, Benkirane M.
    Nat Cell Biol; 2003 Aug 09; 5(8):754-61. PubMed ID: 12883554
    [Abstract] [Full Text] [Related]

  • 28. Inhibition of HIV-1 transcription and virus replication using soluble Tat peptide analogs.
    Kashanchi F, Sadaie MR, Brady JN.
    Virology; 1997 Jan 20; 227(2):431-8. PubMed ID: 9018142
    [Abstract] [Full Text] [Related]

  • 29. New human gene encoding a positive modulator of HIV Tat-mediated transactivation.
    Shibuya H, Irie K, Ninomiya-Tsuji J, Goebl M, Taniguchi T, Matsumoto K.
    Nature; 1992 Jun 25; 357(6380):700-2. PubMed ID: 1377363
    [Abstract] [Full Text] [Related]

  • 30. A sensitive promoter assay based on the transcriptional activator Tat of the HIV-1 virus.
    Koken SE, van Wamel J, Berkhout B.
    Gene; 1994 Jul 08; 144(2):243-7. PubMed ID: 8039709
    [Abstract] [Full Text] [Related]

  • 31. tat regulates binding of the human immunodeficiency virus trans-activating region RNA loop-binding protein TRP-185.
    Wu F, Garcia J, Sigman D, Gaynor R.
    Genes Dev; 1991 Nov 08; 5(11):2128-40. PubMed ID: 1936997
    [Abstract] [Full Text] [Related]

  • 32. Optimal Tat-mediated activation of the HIV-1 LTR promoter requires a full-length TAR RNA hairpin.
    Verhoef K, Tijms M, Berkhout B.
    Nucleic Acids Res; 1997 Feb 01; 25(3):496-502. PubMed ID: 9016587
    [Abstract] [Full Text] [Related]

  • 33. Effects of the human immunodeficiency virus type 1 Tat protein on the expression of inflammatory cytokines.
    Buonaguro L, Barillari G, Chang HK, Bohan CA, Kao V, Morgan R, Gallo RC, Ensoli B.
    J Virol; 1992 Dec 01; 66(12):7159-67. PubMed ID: 1279199
    [Abstract] [Full Text] [Related]

  • 34. Camptothecin inhibits Tat-mediated transactivation of type 1 human immunodeficiency virus.
    Li CJ, Wang C, Pardee AB.
    J Biol Chem; 1994 Mar 11; 269(10):7051-4. PubMed ID: 8125909
    [Abstract] [Full Text] [Related]

  • 35. Cytokine augmentation of HIV-1 LTR-driven gene expression in neural cells.
    Swingler S, Easton A, Morris A.
    AIDS Res Hum Retroviruses; 1992 Apr 11; 8(4):487-93. PubMed ID: 1599755
    [Abstract] [Full Text] [Related]

  • 36. Trans-activation of the long terminal repeat of human immunodeficiency virus type 1 by the parvovirus B19 NS1 gene product.
    Sol N, Morinet F, Alizon M, Hazan U.
    J Gen Virol; 1993 Sep 11; 74 ( Pt 9)():2011-4. PubMed ID: 8376975
    [Abstract] [Full Text] [Related]

  • 37. Inhibition of HIV-1 Tat-mediated transactivation by quinacrine and chloroquine.
    Jiang MC, Lin JK, Chen SS.
    Biochem Biophys Res Commun; 1996 Sep 04; 226(1):1-7. PubMed ID: 8806583
    [Abstract] [Full Text] [Related]

  • 38. Functional comparison of transactivation by simian immunodeficiency virus from rhesus macaques and human immunodeficiency virus type 1.
    Viglianti GA, Mullins JI.
    J Virol; 1988 Dec 04; 62(12):4523-32. PubMed ID: 2846868
    [Abstract] [Full Text] [Related]

  • 39. The HIV-1 transactivator protein Tat is a potent inducer of the human DNA repair enzyme beta-polymerase.
    Srivastava DK, Tendler CL, Milani D, English MA, Licht JD, Wilson SH.
    AIDS; 2001 Mar 09; 15(4):433-40. PubMed ID: 11242139
    [Abstract] [Full Text] [Related]

  • 40. Cytomegalovirus activates transcription directed by the long terminal repeat of human immunodeficiency virus type 1.
    Barry PA, Pratt-Lowe E, Peterlin BM, Luciw PA.
    J Virol; 1990 Jun 09; 64(6):2932-40. PubMed ID: 2159554
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 12.